N 3 (181) 2022. P. 50–52

DAMAGE TO THE VASCULAR PLATELET LANKA TO HEMOSTASIS IN PATIENTS WITH COVID-19 WITH CONCOMITANT CIRCULATORY DIABETES

T. V. Chaban, V. M. Bocharov, S. M. Soltyk

Odesa National Medical University, Odesa, Ukraine

DOI 10.32782/2226-2008-2022-3-11

The COVID-19 epidemic, caused by a new coronavirus, is characterized by a severe course in patients with, diabetes mellitus (DM),the non- infectious epidemy of which occurs last years. According to the International Diabetes Federation, there are 463 million people in the world with diabetes. The severity of the COVID-19 epidemic is in increased due to the frequent combination of theese two pathologies. Based on knowledge from of previous influenza epidemics and resent COVID-19 pandemic data, it can be stated that diabetes and obesity are predictors of severe COVID-19 and death. On the other hand, SARS-CoV-2 may exacerbate the course of diabetes, causing a significant imbalance of the components of the vascular – platelet hemostasis system with the development of disorders characterized by activation of the blood coagulation system. The correlation between coronavirus infection and diabetes, the consequences of their interaction were provided in the article. The severity of the disease determines the tactics of treatment and the choice of antidiabetic therapy.

Key words: coronavirus infection COVID – 19, diabetes mellitus, hemostasis system, vascular – platelet hemostasis.

REFERENCES

  1. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q. Prevalence of comorbidities and its effects in patients infected with SARSCoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95. doi:10.1016/j.ijid.2020.03.
  2. Yang L, Chan KP, Lee RS, Chan WM, Lai HK, Thach TQ et al. Obesity and influenza associated mortality: evidence from an elderly cohort in Hong Kong. Prev Med. 2013;56(2):118–123.
  3. Morgan OW, Bramley A, Fowlkes A, Freedman DS, Taylor TH, Gargiullo P et al. Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A (N1) disease. PLoS One. 2010;15;5(3):e9694. doi:10.1371/journal. pone.0009694.
  4. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell LF, Chernyak Y et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. Br Med J. 2020;369: m1966. doi.org/10.1136/bmj.m1966.
  5. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020. [Ahead of print, published online 9 April 2020]. doi:10.1002/oby.22831.
  6. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis. 2020. [Ahead of print, published online 9 April 2020]. doi:10.1093/cid/ciaa415.
  7. Xue T, Li Q, Zhang Q, Lin W, Wen J, Li L et al. Blood glucose levels in elderly subjects with type 2 diabetes during COVID-19 outbreak: a retrospective study in a single center. medRxiv. 2020. [Рublished online 2 April 2020]. doi:10.1101/2020.03.31.20048579.
  8. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE 2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–590. doi:10.1007/s00134-020-05985-9.
  9. Turner AJ, Hooper NM. The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci. 2002;23(4):177–183.
  10. Batlle D, Soler MJ, And Ye M. ACE2 and Diabetes: ACE of ACEs? Diabetes. 2010;59(12):2994–2996. doi:10.2337/db10-1205.
  11. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes. 2004;53(4):989–997.
  12. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D. Glomerular localization and expression of angiotensin-convertingenzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol. 2006;17(11):3067–3075.
  13. Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int. 2008;74(12):1610–1616.
  14. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al. SARS-CoV-2 cell entry depends on ACE 2 and TMPRSS 2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280. doi:10.1016/j. cell.2020.02.052.
  15. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Singlecell RNA expression profiling of ACE 2, the putative receptor of Wuhan COVID-19. 2020. [Ahead of print, published online 9 April 2020]. doi.org/10.1101/2020.01.26.919985.
  16. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J Virology. 2020;94(7):127–120. doi:10.1128/JVI.00127-20.
View article PDF